New research in neurofeedback is showing promise for those with autism, ADHD, Parkinson’s disease, and chronic pain conditions like fibromyalgia. Can it help those with environmental intolerances, too?
Ashok Gupta has announced the publication of the Clinical Audit Study this month on Gupta Amygdala Retraining™ treatments for ME/CFS, Fibromyalgia and MCS.
The creator of the Dynamic Neural Retraining System™ talks face-to-face with the author of The Brain That Changes Itself about chemical intolerance and the promise of a brain plasticity treatment approach.
The Mayo Clinic is conducting a pilot study of the Gupta Amygdala Retraining™ Programme for patients with chronic fatigue syndrome (CFS) and fibromyalgia (FMS).
HealthDay News reports: New tools that use different colors of light to silence brain activity could lead to new treatments for disorders such as epilepsy, chronic pain, Parkinson’s disease and brain injury.
The NY Times recently reported a fascinating story about Gregg Mozgala, a 31-year-old actor with cerebral palsy, whose body movements were transformed after working with a choreographer.
MCS America’s article “Preying on the Desperate: Miracle Cures Hold False Promise” by Lourdes Salvador and Linda Sepp is full of disinformation.
Planet Thrive founder Julie Genser interviews Ashok Gupta to get a more in-depth view into the Amygdala Retraining™ Program for CFS/ME and related disorders.
Fibromyalgia drug Lyrica and its former less potent version Neurontin have both been shown to “block the formation of new brain synapses, drastically reducing the potential for rejuvenating brain plasticity.”
Ashok Gupta has written a draft medical paper which explains how the recent XMRV findings fit with his Amygdala Hyperarousal Model for ME/CFS and Fibromyalgia.
